COMPANY PROFILE

ImCheck Therapeutics

Explore full profile

Designing and developing a new generation of immunotherapy antibodies

Marseille, FranceFounded 2015Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About ImCheck Therapeutics

ImCheck Therapeutics is at the forefront of developing next-generation immunotherapeutic antibodies, focusing on the modulation of the immune system through the butyrophilin BTN and BTN-like BTNL superfamily of checkpoint molecules. The company targets a broad spectrum of diseases, including cancer, infectious diseases, and autoimmune disorders. Operating within the biopharmaceutical sector, ImCheck leverages its proprietary knowledge to design innovative treatments that harness the body's immune response. The business model revolves around research and development, with revenue generation primarily through partnerships, licensing agreements, and potential future sales of approved therapies. ImCheck's clientele includes healthcare providers, research institutions, and potentially patients who benefit from advanced immunotherapy solutions. The company is actively involved in clinical trials, such as the Phase I/IIa EVICTION trial for ICT01, to validate the efficacy and safety of its therapeutic candidates.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2015
Headquarters: Marseille, France
Employees: 47
Open positions: None listed
Dealroom signal: 66.5/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Autoimmune, Immune System, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, radar de l'innovation, observatoire industrial tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Oct 2025	$385M	$385M	Ipsen	↗
GRANTOther financing	Aug 2024	$22M	—	France 2030	↗

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Growth	Margin
2026	—	—
2025	—	—
2024	—	—
2023	—	—
2022	—	—
2021	—	—
2020	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

ImCheck Therapeutics website traffic

Latest recorded traffic for ImCheck Therapeutics is 1.3K monthly website visits, up 1200% over the last three months. ImCheck Therapeutics's team declined 16.1% over the past year.

Latest monthly visits1.3K 3-month web change+1200% 1-year team growth-16.1%

Monthly website visitsNov 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TOTollysDevelopment of innovative immunotherapies targeting cancer through the modulation of the TLR3 receptor	Lyon, France	Closed	2	$3.4M	$10M
STStimunityTurn cancer immunotherapies active in most patient	Paris, France	Operational
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
THTHERAVECTYSTHERAVECTYS develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.	Paris, France	Operational
HEHEPHAISTOS-PharmaDeveloping Tomorrow’s immuno-oncology and modulator therapy \| A single platform for defeating cancer and much more	Orsay, France	Operational
VBVentuno BiotechCancer immunotherapies designed to enhance the immune system's response against difficult-to-treat tumors	Lyon, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
OBOne BiosciencesOperating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases	Paris, France	Operational